Therapeutic development of cystic fibrosis correctors
Therapeutic development of cystic fibrosis correctors
批准号:
182373
负责人:
Thomas David Y
金额:
$34.97万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2009
资助国家:
加拿大
项目状态:
已结题
起止时间:
2009-03-01 至 2011-03-01
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Cystic fibrosis is the most common fatal genetic disease. It affects at least 80,000 patients worldwide, imposing enormous burdens on the patient, their families and on society. Advances in early detection, antibiotic therapy and care have seen the media
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Endoplasmic Reticulum Proteostasis to rescue Alpha1 AntiTrypsin Deficiency (acronym ERAAT) This is a proposal to the -Rare Joint Transnational Call for Proposals 2017 "Transnational Research Projects for Innovative Therapeutic Approaches for Rare Disease
-
批准号:373006
-
项目类别:Operating Grants
-
资助金额:$16.35万
-
财政年份:2017
-
负责人:Thomas David Y
-
依托单位:
Canada Research Chair Tier 1
-
批准号:315468
-
项目类别:
-
资助金额:$101.99万
-
财政年份:2014
-
负责人:Thomas David Y
-
依托单位:
Biological variability of the response to protein trafficking correctors of cystic fibrosis
-
批准号:237564
-
项目类别:Operating Grants
-
资助金额:$71.78万
-
财政年份:2011
-
负责人:Thomas David Y
-
依托单位:
Cystic Fibrosis and ER Quality Control.
-
批准号:181331
-
项目类别:Operating Grants
-
资助金额:$59.97万
-
财政年份:2009
-
负责人:Thomas David Y
-
依托单位:
CIHR Strategic Training Program in Chemical Biology
-
批准号:176961
-
项目类别:Operating Grants
-
资助金额:$112.07万
-
财政年份:2008
-
负责人:Thomas David Y
-
依托单位:
Chemical correctors of deltaF508 CFTR trafficking
-
批准号:183640
-
项目类别:Operating Grants
-
资助金额:$26.67万
-
财政年份:2008
-
负责人:Thomas David Y
-
依托单位:
海外基金